Evidence map›Paper›PMID 39372698›Full record

ArticleThe Pan African medical journal2024

[Livedo reticularis following administration of COVID-19 vaccine: a case report].

Meryem Ouhaddach, Mouna Zahlane, Lamiaâ Essaadouni

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in The Pan African medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Meryem OuhaddachService de Médecine Interne, Hôpital Arrazi CHU Mohamed VI, Marrakech, Maroc.
Mouna ZahlaneService de Médecine Interne, Hôpital Arrazi CHU Mohamed VI, Marrakech, Maroc.
Lamiaâ EssaadouniService de Médecine Interne, Hôpital Arrazi CHU Mohamed VI, Marrakech, Maroc.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 has made it crucial to develop safe vaccines. Three main types of vaccines are currently available. Although they have proven to be very secure, they have caused various adverse effects. We here report a rare case of livedo reticularis following the administration of COVID-19 vaccine in a 54-year-old woman. It occurred 24 hours after vaccination, accompanied by respiratory, digestive, and neurological disorders and deterioration in general condition. Examinations revealed skin lesions compatible with livedo reticularis, mild inflammatory syndrome and hypercholesterolemia. Imaging showed no abnormalities. Immunological tests were positive for lupus anticoagulant. The patient received symptomatic treatment, with improvement in neurological and joint symptoms and a slight regression of skin rashes. After three months, the lupus anticoagulant test remained positive, confirming post-vaccination antiphospholipid syndrome (APS). The association of livedo reticularis with COVID-19 vaccine should not be underestimated and its degree of severity remains to be determined. More data and cases need to be collected for a more in-depth and detailed analysis.

Indexed as

Antiphospholipid SyndromeCOVID-19 VaccinesLivedo ReticularisCOVID-19FemaleHumansLupus Coagulation InhibitorMiddle AgedVaccinationCOVID-19 VaccinesLupus Coagulation Inhibitoradverse reactionLivedo reticularisvaccination

Identifiers

PMID39372698
PMCPMC11453108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.